Last updated: 11/03/2021 10:50:07
A study to investigate the safety and immunogenicity of different formulations of GSK Biologicals’ Meningococcal ACWY conjugate vaccine (GSK3536820A and Menveo) administered to healthy adults 18 to 40 years of age
EudraCT ID
EU CT Number
Not applicable
Trial status
Completed
Completed
Trial overview
Official title: Immunogenicity, reactogenicity and safety of two formulations of GSK Biologicals’ Meningococcal ACWY conjugate vaccine (GSK3536820A and Menveo) in healthy adults 18 to 40 years of age
Trial description: MenACWY (Menveo) is a GSK vaccine intended for protection against disease caused by meningococcal bacteria groups A, C, W and Y in infants, children and adults, licensed in more than 60 countries. The purpose of this study is to compare the immunogenicity of the currently licensed MenACWY vaccine with the investigational MenACWY liquid vaccine.
Primary purpose:
Prevention
Trial design:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Allocation:
Randomized
Primary outcomes:
Adjusted Human Serum Bactericidal Activity (hSBA) Geometric Mean Titers (GMTs) against N. meningitidis serogroup A for each vaccine group, and between-group ratios
Timeframe: At Day 29
Secondary outcomes:
hSBA GMTs against each of the N.meningitidis serogroups A, C, W and Y for each vaccine group, and between-group ratios
Timeframe: At Day 1 and Day 29
Within-group Geometric Mean Ratios (GMRs) against each of the N.meningitidis serogroups A, C, W and Y
Timeframe: At Day 29
Percentages of subjects with a ≥4 fold rise in hSBA antibody titers for each of the N.meningitidis serogroups A, C,W and Y for each vaccine group, and between-group differences
Timeframe: At Day 29
Percentages of subjects with hSBA titers ≥8 against each of the N. meningitidis serogroups A, C, W and Y for each vaccine group, and between-group differences
Timeframe: At Day 1 and Day 29
Percentages of subjects with hSBA titers ≥LLOQ against each of the N. meningitidis serogroups A, C, W and Y for each vaccine group, and between-group differences
Timeframe: At Day 1 and Day 29
Number of subjects reported with solicited local and systemic AEs
Timeframe: From Day 1 (6 hours) to Day 7 after vaccination
Number of subjects reported with other indicators of reactogenicity
Timeframe: From Day 1 to Day 7 after vaccination
Number of subjects reported with any unsolicited AEs within 29 days after vaccination
Timeframe: From Day 1 to Day 29 after vaccination
Number of subjects reported with AEs leading to withdrawal, medically attended AEs and serious adverse events (SAEs)
Timeframe: From Day 1 to Day 181 (during the entire study period)
Number of subjects reported with any unsolicited adverse events (AEs) within 30 minutes after vaccination
Timeframe: Within 30 minutes after vaccination at Day 1
Interventions:
Biological/vaccine: MenACWY liquid vaccine with approximately 30% MenA FS (GSK3536820A)
Biological/vaccine: Licensed GSK MenACWY vaccine (Menveo)
Enrollment:
996
Observational study model:
Not applicable
Primary completion date:
2019-17-01
Time perspective:
Not applicable
Clinical publications:
Vandermeulen C, Leroux-Roels I, Vandeleur J, Staniscia T, Girard G, Ferguson M, Icardi G, Schwarz TF, Neville AM, Nolan T, Cinquetti S, Akhund T, Van Huyneghem S, Aggravi M, Kunnel B, De Wergifosse B, Di Domenico GF, Costantini M, Singh PV, Fragapane E, Lattanzi M, Pellegrini M. A new fully liquid presentation of MenACWY-CRM conjugate vaccine: Results from a multicentre, randomised, controlled, observer-blind study. Vaccine. 2021;39(45):6628-6636.
DOI: http://dx.doi.org/ 10.1016/j.vaccine.2021.09.068
Medical condition
Infections, Meningococcal
Product
GSK3536820A
Collaborators
Not applicable
Study date(s)
September 2018 to June 2019
Type
Interventional
Phase
2
Participation criteria
Sex
Female & Male
Age
18 - 40 years
Accepts healthy volunteers
Yes
- 1. Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol or subjects’ parent(s)/Legally Acceptable Respresentative(s) [LAR(s)] who, in the opinion of the investigator, can and will comply, with the requirements of the protocol.
- 2. Written informed consent obtained from the subject/from the parents(s)/LAR(s) of the subject prior to performance of any study specific procedure.
- 1. Anaphylaxis following the administration of vaccine
- 2. Any (clinical) condition that in the judgment of the investigator would make intramuscular injection unsafe and/or represents a contraindication to intramuscular vaccination and blood draws.
Inclusion and exclusion criteria
Inclusion criteria:
- 1. Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol or subjects’ parent(s)/Legally Acceptable Respresentative(s) [LAR(s)] who, in the opinion of the investigator, can and will comply, with the requirements of the protocol. 2. Written informed consent obtained from the subject/from the parents(s)/LAR(s) of the subject prior to performance of any study specific procedure. 3. Written informed assent obtained for subjects below legal age of consent, if required by local regulations, at the time of enrolment. 4. A male or female between, and including, ≥18 to ≤40 YoA at the time of the first vaccination. 5. Healthy subjects as established by medical history and clinical examination before entering into the study. 6. Female subjects of non-childbearing potential may be enrolled in the study.
- Non-childbearing potential is defined as pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy or post-menopause. 7. Female subjects of childbearing potential may be enrolled in the study, if the subject:
- has practiced adequate contraception for 30 days prior to vaccination, and
- has a negative pregnancy test on the day of vaccination, and
- has agreed to continue adequate contraception during the entire treatment period. (approximately 1 month after vaccination).
Exclusion criteria:
- 1. Anaphylaxis following the administration of vaccine 2. Any (clinical) condition that in the judgment of the investigator would make intramuscular injection unsafe and/or represents a contraindication to intramuscular vaccination and blood draws. 3. Any confirmed or suspected immunosuppressive or immunodeficient condition, including HIV infection. 4. Progressive, unstable or uncontrolled clinical conditions. 5. Hypersensitivity, including allergy, to any component of vaccines, medicinal products or medical equipment whose use is foreseen in this study. 6. Hypersensitivity to the active substances or to any of the excipients of the vaccine, including diphtheria toxoid (CRM197), or a life-threatening reaction after previous administration of a vaccine containing similar components. 7. Abnormal function of the immune system resulting from:
- Clinical conditions.
- Systemic administration of corticosteroids (Per os [PO]/ Intravenous [IV]/ Intramuscular [IM]) for more than 14 consecutive days within 90 days prior to informed consent, and until the Day 29 blood draw.
- Administration of antineoplastic and immuno-modulating agents or radiotherapy within 90 days prior to informed consent, and until the Day 29 blood draw. 8. Received immunoglobulins or any blood products within 180 days prior to informed consent. 9. Received an investigational or non-registered medicinal product within 30 days prior to informed consent. 10. Any other clinical condition that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subject due to participation in the study. 11. History of any meningococcal vaccination. 12. Individuals who received any other vaccines within 7 days (for inactivated vaccines) or 14 days (for live vaccines) prior to enrolment in this study or who are planning to receive any vaccine within 28 days from the study vaccines*. * In case an emergency mass vaccination for an unforeseen public health threat (e.g.: a pandemic) is organised by the public health authorities, outside the routine immunization program, the time period described above can be reduced if necessary for that vaccine provided it is licensed and used according to its Summary of Product Characteristics (SmPC) or Prescribing Information and according to the local governmental recommendations and provided a written approval of the Sponsor is obtained. 13. Administration of long-acting immune-modifying drugs at any time during the study period (e.g. infliximab). 14. Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product. (pharmaceutical product or device). 15. Current or previous, confirmed or suspected disease caused by N. meningitidis. 16. Household contact with and/or intimate exposure to an individual with any laboratory confirmed N. meningitidis infection within 60 days prior to study vaccination. 17. Acute disease and/or fever within 3 days prior to study vaccination. Note: enrolment may be postponed/delayed until such transient circumstances have ended.
- Fever is defined as body temperature ≥ 38.0°C / 100.4°F. The preferred location for measuring temperature in this study will be the oral cavity.
- Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory infection) without fever may be enrolled at the discretion of the investigator. 18. Received systemic antibiotic treatment within 3 days prior to study vaccination or blood draw. 19. Study personnel as an immediate family or household member. 20. Pregnant or lactating women.
Trial location(s)
Location
GSK Investigational Site
Adelaide, South Australia, Australia, 5000
Status
Study Complete
Location
GSK Investigational Site
Blacktown, New South Wales, Australia, 2148
Status
Study Complete
Location
GSK Investigational Site
Essen, Nordrhein-Westfalen, Germany, 45355
Status
Study Complete
Location
GSK Investigational Site
Goch, Nordrhein-Westfalen, Germany, 47574
Status
Study Complete
Location
GSK Investigational Site
Gold Coast, Queensland, Australia, 4222
Status
Study Complete
Location
GSK Investigational Site
Kanwal, New South Wales, Australia, 2259
Status
Study Complete
Location
GSK Investigational Site
Mainz, Rheinland-Pfalz, Germany, 55116
Status
Study Complete
Location
GSK Investigational Site
Murdoch, Western Australia, Australia, 6150
Status
Study Complete
Location
GSK Investigational Site
Pointe-Claire, Québec, Canada, H9R 4S3
Status
Study Complete
Location
GSK Investigational Site
Victoria, British Columbia, Canada, V8V 3M9
Status
Study Complete
Study documents
Clinical study report
Available language(s): English
Protocol
Available language(s): English
Statistical analysis plan
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Completed
Actual primary completion date
2019-17-01
Actual study completion date
2019-11-06
Plain language summaries
Summary of results in plain language
Available language(s): English, Dutch (Belgium), French (Belgium), French (Canadian), German, Italian
To view plain language summaries on trialsummaries.com click here.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website